← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV24행 · 1개 프로그램
OverviewMoAPK/PDToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePreclinical
Azathioprine + infliximab (Azathioprine + infliximab)
Nantes University Hospital·Crohn Disease
30 trials
Overview
Program
Azathioprine + infliximab
Overview
Company
Nantes University Hospital
Overview
Modality
ANTIBODY
Overview
Target
Crohn Disease
Overview
Indication
Crohn Disease
Overview
Phase
PRECLINICAL
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
MoA
Mechanism
targeting T cells via surface receptor
MoA
Biomarker
biomarkers, and targeted biologic therapies enables precision-based management, improving visual outcomes and
PK/PD
Species
Rat
PK/PD
Animal (cat.)
Rat
PK/PD
Experiment
Pharmacokinetic
Toxicology
Species
Rat
Toxicology
Animal (cat.)
Rat
Toxicology
Major finding
hepatotoxicity and renal abnormalities which restrict their use in the treatment of RA; new
Clinical
Safety signal
hepatotoxicity and renal abnormalities which restrict their use in the treatment of RA; new
Clinical
Selected reported efficacy
6%
Clinical
Result source
ClinicalTrials.gov NCT00132691
Clinical
Program phase
PRECLINICAL
Clinical
Trial ref
NCT00132691